Sanofi announced the appointment of Muzammil “Muz” Mansuri as a new member of the Executive Committee, effective February 22, 2016. Mansuri joins Sanofi from Gilead Sciences and will take the position of executive vice president, strategy & business development.
Mansuri will be responsible for all Group strategic planning, business development, strategic intelligence, alliance management and the Sanofi Genzyme Bio Ventures fund.
“Muz brings a wealth of experience as a senior executive within the global biopharmaceutical industry,” said Olivier Brandicourt, CEO, Sanofi. “Muz’s deep understanding of business development and strategy of global biopharmaceutical organisations will allow him to contribute significantly to the overall Group strategy and make him a valuable addition to Sanofi and the Executive Committee.”
A dual citizen of the US and United Kingdom, Mansuri has more than 35 years of experience beginning in 1981 with Shell Research Limited where he began as a research scientist. After Shell, he spent several years with Bristol-Myers Company in various R&D roles with increasing responsibility. From 2007 to 2010, Mansuri was chairman and CEO at CGI Pharmaceuticals. Mansuri’s most recently was senior vice president, research & development strategy and corporate development at Gilead Sciences.
Mansuri holds a bachelor of science degree in chemistry and a Ph.D in organic chemistry from the University College London. He held post-doctoral positions at the University of California, Los Angeles (UCLA) and Columbia University.
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.